Raymond James Adjusts PT on Ameriprise Financial to $638 From $582, Maintains Strong Buy Rating

Raymond James raised its price target on Ameriprise Financial to $638 from $582, maintaining a Strong Buy rating. The company's stock is currently trading at $555.59, up 1.55% over 5 days and 13.31% year-to-date.

Original reporting
Published Aug 21, 2026, 10:27 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 4:43 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$AMP
Relevance
5/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

Med
01

Why it matters

The upgrade may prompt traders to add to positions, though broader market drivers dominate.

02

Market read

A modest analyst upgrade with limited material impact.

03

What to watch

Potential headwinds from interest-rate environment not addressed.

Relevance 5/10Novelty 5/10Timing: today

Background

Analyst price target adjustments are routine but can influence short-term trading.

Market effects

May lift sentiment in the financial services sector.

Limited to U.S. markets where Ameriprise trades.

Low global impact beyond U.S. investors.

Counterpoint

The target raise could be premature without earnings support.

Key entities

  • Ameriprise Financial

    U.S. financial services firm (ticker AMRN).

  • Raymond James

    Research firm issuing the price target revision.

Related articles

$AMPMed

AMP (ASX:AMP) Is Up 12.6% After Strong Half-Year Profit Lift - What's Changed

AMP Limited reported half-year results to 30 June 2026, with revenue up to A$1,425 million and net income to A$154 million. Basic EPS from continuing operations rose to A$0.061. The article links the profit lift to efficiency and business mix changes, notes margin and cost risks, and mentions Richard Millington’s appointment to lead Employer Adviser Partnerships.

$AMPMed

AMP Shares At Highest Level In Years, Lead ASX 200 Gainers

AMP Ltd shares (ASX:AMP) rose 5.96% to A$2.31, near a 2018 high, after its half-year 2026 results. Assets under management grew 8.2% to $167.6B. Platforms net cash flows rose 33% to $3.1B, and Superannuation net inflows were $76M. Underlying NPAT rose 33% to $174M. Interim dividend was 3c (20% franked) and AMP plans a $150M buyback.

$AMPMedAI 8/10

Why is AMP stock surging today?

AMP shares rose 6% to a seven-year high of A$2.31 after the company reported a strong half-year. Underlying net profit after tax rose 33% to AUD 174 million, beating analyst consensus of about AUD 142 million and the company’s AUD 170–180 million guidance. Statutory NPAT rose 57% to AUD 154 million. AMP also announced a AUD 150 million buyback and raised its dividend payout ratio to 41% from 35%.

$AMPMed

AMP H1 profit jumps 57% on China partnerships, wealth gains

AMP Limited reported a 57% rise in half-year net profit to A$154 million for the six months ended June 30, driven by stronger China partnerships and wealth platforms that offset weaker banking. Revenue rose 4% to A$1.425 billion. Underlying profit increased 32.8% to A$174 million. The board declared a 3.0c interim dividend and approved an additional on-market buyback tranche up to A$150 million.

$AMPMed

40-year investor loan with 10 years of IO launches

AMP Bank launched “Equity Flex,” a 40-year loan for real estate investors with LVR up to 80%. It offers 6 to 10 years interest-only, with rates starting at 6.54% (60% LVR) and 6.59% (80% LVR), and fixed P&I at 6.39% p.a. The bank cites investor cash-flow needs amid higher rates and tax changes.